Objective: This study explored if the patient-experience and the affect heuristic influenced improvements in painful symptoms, in response to open label placebo injections in patients with knee OA. It furthermore explored if other cognitive biases or heuristics were involved in the response to open-label placebo.

Method: A mixed method study in a pre-specified knee OA cohort. The influence of patient-experience, and the affect heuristic, on change in painful symptoms in response to an open-label placebo injection, were assessed using a questionnaire and multivariate linear regression. The group concept mapping method was used to characterise the expectations and hopes regarding the effect of an open-label placebo injection in non-responders and responders, defined as the lower- and upper quartile of the ΔVAS pain scores.

Results: 103 participants received the questionnaire, and 60 finalised questionnaires were included in the analysis showing that the reduction in pain was associated with the patient-experience and that the affect heuristic acted as an effect modifier. Three workshops were held for non-responders ( ​= ​13) and responders ( ​= ​15) each generating respectively 113 and 119 statements. It was found that the two groups reported different expectations and hopes for the open label placebo injections.

Conclusions: The patient-experience influenced the response to an open label placebo injection in patients with knee OA, and this influence was moderated by the strength of the affect heuristic. Furthermore, non-responders and responders reported different hopes and expectation towards the open label placebo injection indicating the presence of the optimism bias in the responder group.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836500PMC
http://dx.doi.org/10.1016/j.ocarto.2025.100574DOI Listing

Publication Analysis

Top Keywords

open label
20
affect heuristic
16
label placebo
16
placebo injection
16
patients knee
12
patient-experience affect
12
group concept
8
concept mapping
8
painful symptoms
8
symptoms response
8

Similar Publications

Purpose: To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).

Methods: Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment.

View Article and Find Full Text PDF

Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.

View Article and Find Full Text PDF

Background And Objective: For treating community-acquired pneumonia (CAP) in adults, early switching from injectable to oral antimicrobials (switch therapy) is accepted once the clinical course is favorable. Lascufloxacin (LSFX) is a quinolone antibacterial agent, available in intravenous and oral formulations, demonstrating antibacterial activity against a relatively broad spectrum of community-onset pneumonia (COP). No switch therapy using the same drug from injectable to oral antimicrobials has been reported; therefore, we conducted the study to confirm the efficacy and safety of the switch therapy using LSFX.

View Article and Find Full Text PDF

Background: Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a diagnosis of axSpA with a duration of axial symptoms equal to or less than 2 years. Tofacitinib is a Janus kinase (JAK) inhibitor for the treatment of ankylosing spondylitis.

View Article and Find Full Text PDF

Bacterial pathogens deliver effector proteins into host cells by deploying sophisticated secretion systems. This effector translocation during host-pathogen interactions is a prerequisite for the manipulation of host cells and organisms and is important for pathogenesis. Analyses of dynamics and kinetics of translocation, subcellular localization, and cellular targets of effector proteins lead to understanding the mode of action and function of effector proteins in host-pathogen interplay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!